Peptides, explained: Answers to your top questions

Then how can they be sold? And why is everyone talking about peptides right now?

There is a regulatory gray space that has recently experienced a bout of whiplash.

For years, compounding pharmacies (facilities that custom-mix medications for individual patients) served as the primary legal pipeline for peptides like BPC-157 and TB-500. While compounded drugs are not FDA-approved, the FDA permits their sale when a patient has a specific medical need that no existing approved product can meet. Chronic tendon injuries, for example, are notoriously difficult to treat, and patients working closely with their physicians may be open to trying therapies that lack formal human trials. Because compounding pharmacies typically require a doctor’s prescription, patients generally access these drugs under at least some degree of medical supervision.

Then, in late 2023, the FDA moved 19 of the most popular peptides to the Category 2 list, which is essentially a “do not compound” designation. There was growing misuse of telehealth on a scale that demanded a response, and the FDA cited safety concerns, including immune reactions, pancreatitis, and accelerated growth of cancerous cells.

But demand didn’t disappear, and in its place, a “gray market” appeared. Overseas suppliers, like in China, began selling these compounds online, labeled “for research use only” to sidestep FDA jurisdiction. (It would be illegal under the Federal Food, Drug, and Cosmetic Act for a manufacturer to sell an unapproved product in the U.S. market for the “diagnosis, cure, mitigation, treatment, or prevention of disease.”)

Then, on February 27, 2026, HHS Secretary RFK Jr. went on the Joe Rogan podcast and announced that roughly 14 of those 19 restricted peptides would be re-categorized such that the FDA would permit them to be compounded once again. Within hours, posts declared “peptides are legal again,” wellness clinics started marketing aggressively, and money started flowing in.

As of today, though, no formal FDA rule has actually changed. The actual process (rule-making, supply chain readiness, and possibly public comment) will take months, at a minimum. The FDA announced a formal advisory committee meeting for this summer to review whether several peptides should be added back to the compounding available list.

Why do people skeptical of vaccines embrace peptides that have even less human evidence?

At least three strong overlapping forces are at play:

1. Marketing and association. Peptides have been embraced by the wellness and biohacking world, giving them a “natural” and “holistic” halo. But it’s not just how they are marketed, it’s who is marketing them. Influencers have large, loyal audiences and are a genuine force in shaping health decisions today. Their endorsement carries a kind of peer trust that pharmaceutical companies simply cannot replicate. Big Pharma has lost trust due to overcharging for drugs and overmarking products leading to harm, like Vioxx 20 years ago. Vaccines, by contrast, are associated with Big Pharma that markets them and the government health agencies that recommend them.
2. Logical fallacies
   1. Nature fallacy. Peptides feel familiar because they already exist in the body, so the perceived risk feels negligible. How dangerous can something be if your body already makes it? But this ignores that dose, delivery method, and context change everything, and that many of the peptides being sold are synthetic analogs rather than identical copies of what your body produces.
   2. Post hoc fallacy. When someone injects a peptide, and their tendon feels better two weeks later, the peptide gets the credit, even though tendons heal on their own, and there was no control group. This is the same logic that drives vaccine skepticism (“Someone I know got the shot and then died”), but applied asymmetrically.
3. Legitimate grievances. Some support derives from frustrations with conventional medicine’s blind spots, profit motives, and the experience many patients have of being told their chronic pain or slow-healing injury is something they simply have to live with. Peptides, by contrast, offer a sense of agency and a plausible biological mechanism, which is compelling when the standard of care has let you down.

What does this mean for you?

For people managing chronic conditions that haven’t responded to conventional treatment, the cost of physician visits, specialist referrals, and insurance hurdles makes gray-market peptides appealing because they require no prescription and are often cheaper.

Peptides have found an equally eager audience in the wellness and longevity crowd (athletes, biohackers, and optimization-minded people) who see them as a tool for faster recovery, better performance, and aging on their own terms.

But, ultimately, benefits need to outweigh risks. So, here are some important considerations to take into account:

• There are some reported and theoretical risks. For example, many peptides are thought to act on pathways important for tissue growth, including blood vessel growth, which should be taken very seriously because these processes drive cancer when they go awry.
• Reclassification is not the same as approval. Availability of peptides on the gray market, or even by prescription at a compounding pharmacy, does not mean they have been reviewed by the FDA as safe and effective. That requires years of human clinical trials and a separate, far more rigorous process.
• How you access them matters. Having a physician evaluate your specific situation and prescribe through a licensed compounding pharmacy is meaningfully different from self-injecting something ordered online. Unverified sources can contain impurities, be incorrectly dosed, and produce unpredictable reactions that end up costing far more to treat.

Bottom line

Peptides like insulin and GLP-1s have been lifesaving; other compounds may ultimately prove safe and useful for patient care, while others are just biologically implausible. But we are in a wave of enthusiasm and regulatory uncertainty, where people are making health decisions based on limited information, while others profit from it.

That is worth knowing before you click “add to cart.”

Love, YLE

---

Another big thanks to Dr. Aaron Kesselheim, an expert in pharmacoepidemiology and pharmacoeconomics, who reviewed this post and provided really helpful feedback.

Your Local Epidemiologist (YLE) is founded and operated by Dr. Katelyn Jetelina, MPH PhD—an epidemiologist, wife, and mom of two little girls. YLE reaches over 425,000 people in over 132 countries with one goal: “Translate” the ever-evolving public health science so that people will be well-equipped to make evidence-based decisions. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members